Skor PD-L1 nggambarake pewarnaan ing sampel jaringan—dudu kemungkinan pribadi panjenengan kanggo kasil entuk perawatan. Cara penilaian, diagnosis kanker, lan kombinasi obat sing diusulake nemtokake apa sing bisa didhukung dening asil kasebut.
Pokok-pokok penting
- Asil tes PD-L1 ngukur pewarnaan protein ing jaringan kanker; asil kasebut dudu asil tes getih rutin utawa tes skrining kanker.
- TPS yaiku persentase sel tumor sing isih urip kanthi pewarnaan membran sing nyukupi syarat, dilapurake saka 0% nganti 100%.
- CPS ngetung sel tumor, limfosit, lan makrofag positif PD-L1 sing nyukupi syarat, mbagi nganggo jumlah sel tumor sing isih urip, banjur dikalikan 100; skor sing dilapurake diwatesi maksimal 100.
- Skor sing beda-beda ora bisa diowahi: TPS 10% bisa bebarengan karo CPS 10, CPS 25, utawa nilai liyane gumantung saka pewarnaan sel imun.
- Ambang wates kayata TPS 1%, TPS 50%, CPS 1, lan CPS 10 ditrapake kanggo kahanan kanker lan perawatan tartamtu—ora kanggo saben imunoterapi.
- Asil positif bisa ndhukung pilihan perawatan nanging ora njamin manfaat; skor 50 ora ateges kemungkinan respons 50%.
- asil negatif ora mesthi ngilangi imunoterapi amarga sawetara kombinasi lan perawatan sing ditemtokake biomarker ora mbutuhake PD-L1 positif.
- Kecukupan sampel iku penting: sawetara protokol skor sing umum digunakake mbutuhake paling ora 100 sel tumor sing isih urip, nanging laboratorium kudu ngetrapake aturan khusus miturut indikasi.
Apa sejatine sing dituduhake asil tes PD-L1 marang panjenengan?
Asil tes PD-L1 nggambaraké pewarnaan protein ing jaringan kanker. TPS ngitung persentase sel tumor sing diwarnani; CPS uga nyakup sel imun tartamtu sing diwarnani. Ora ana skor siji wae sing mutusake perawatan: jinis kanker, stadium, uji, lan regimen nemtokake ambang sing cocog, lan asil positif utawa negatif ora njamin manfaat utawa ngilangi pilihan perawatan.
PD-L1, utawa programmed death-ligand 1, bisa kaiket karo reseptor PD-1 ing sel imun lan nyuda aktivitase. Obat sing nargetake interaksi iki bisa mulihake aktivitas imun antikanker, nanging pangukuran 1 protein ora nyakup kabeh faktor sing nemtokake apa sel imun bisa ngenali lan ngendhaleni kanker.
Asil PD-L1 jaringan biasane diasilake kanthi imunohistokimia, sing nggunakake antibodi kanggo nuduhake lokasi protein ing sampel sing diawetake. Angka sing dilapurake nggambaraké sel ing irisan jaringan sing dipilih—dudu saben sel kanker ing sakujur awak—lan 2 sampel saka panggonan sing béda bisa ngasilake asil sing béda.
Kantesti iku sawijining Analisa tes getih AI, dudu pangganti patologi jaringan utawa keputusan perawatan onkologi. Kita organisasi lan ruang lingkup klinis mbedakake dhukungan edukatif kanggo asil laboratorium saka keputusan sing mbutuhake laporan patologi asli, pencitraan, lan regimen perawatan sing diusulake bebarengan.
Miwiti kanthi 4 rincian sadurunge nafsirake angka kasebut: diagnosis kanker, apa skore CPS utawa TPS, uji sing digunakake, lan perawatan sing lagi dipertimbangkan. Laporan sing mung nyebut PD-L1 positif ninggalake kekurangan informasi sing wigati sacara klinis; jaluk cara penilaian lan asil numerik.
Tegese skor TPS PD-L1: persentase sel tumor
Skor proporsi tumor, utawa TPS, yaiku persentase sel tumor sing isih urip sing nuduhake pewarnaan PD-L1 membran parsial utawa lengkap sing nyukupi kriteria. TPS kisarané saka 0% nganti 100%; sel imun ora kalebu ing pembilangé, sanajan pewarnaané kuwat ing jejere sel kanker.
TPS = sel tumor sing isih urip lan positif PD-L1 ÷ kabèh sel tumor sing isih urip × 100%. Ing lapangan jaringan hipotetis sing ngemot 200 sel tumor sing isih urip, 80 sel positif sing nyukupi kriteria ngasilake TPS 40%; limfosit sing diwarnani ing cedhaké ora ngowahi petungan iki, sanajan bisa mengaruhi sistem skor liyane.
Membrane location matters more than visual darkness alone. For commonly used TPS methods, weak qualifying membrane staining can count, whereas staining limited to tumor-cell cytoplasm does not establish a positive tumor cell; TPS 1% therefore describes the fraction of qualifying cells, not a required intensity grade.
Cutoffs such as TPS 1% lan TPS 50% were used to define populations in particular lung-cancer trials and treatment pathways. They are not boundaries between harmless and dangerous cancer, and crossing 50% does not create an abrupt biological switch from treatment resistance to guaranteed sensitivity.
Read the exact reporting format: TPS <1%, TPS 1–49%, and TPS ≥50% provide different detail from a single positive flag. Our explanation of asil kualitatif tinimbang kuantitatif covers why a category cannot replace a number, although PD-L1 uses tissue-specific—not blood-reference-range—rules.
Tegese skor CPS PD-L1: apa sebabe sel imun diitung
Combined positive score, utawa CPS, includes qualifying PD-L1-positive tumor cells, lymphocytes, and macrophages. CPS divides their combined count by the number of viable tumor cells and multiplies by 100; the denominator does not become all cells simply because immune cells enter the numerator.
CPS = positive tumor cells plus qualifying positive lymphocytes and macrophages ÷ viable tumor cells × 100. In a hypothetical sample with 500 viable tumor cells, 50 positive tumor cells, and 75 qualifying positive immune cells, CPS is 25; the tumor-cell-only TPS would be 10%.
The reported CPS is capped at 100, even if the uncapped arithmetic would exceed 100 because many qualifying immune cells surround relatively few tumor cells. CPS is a unitless score, not a percentage of all cells, a blood concentration, or a probability that immunotherapy will work.
Not every stained immune cell belongs in the CPS count. The pathologist applies the assay manual's rules for eligible lymphocytes and macrophages associated with the tumor; neutrophils, unrelated inflammatory areas, and nonviable tissue are not simply added because a slide contains visible staining.
A CPS of 20 can arise from more than 1 cellular pattern: abundant tumor-cell staining, substantial immune-cell staining, or both. This denominator issue resembles the distinction between cell counts and percentages, but a circulating monocyte count cannot supply the tissue information needed to calculate CPS.
Apa sebabe CPS lan TPS ora bisa diganti utawa dikonversi
CPS and TPS are not interchangeable because they count different cells and were validated in different treatment settings. A TPS of 10% cannot be converted reliably into CPS 10, and a CPS of 20 does not establish that 20% of tumor cells stain.
Consider 2 hypothetical specimens with 500 viable tumor cells and 50 positive tumor cells each. The first has no qualifying positive immune cells and gives TPS 10% with CPS 10; the second contains 75 qualifying positive immune cells and gives the same TPS 10% with CPS 25.
The reverse inference fails too. A hypothetical CPS 20 could result from 20 positive tumor cells among 100 tumor cells, or from 5 positive tumor cells plus 15 qualifying positive immune cells; those examples have TPS 20% and TPS 5%, respectively, despite identical CPS values.
An immune-cell score, sometimes abbreviated IC, is another system rather than a third spelling of CPS. Some IC methods measure the proportion of tumor area occupied by stained immune cells, so an IC result of 1% must be interpreted using its own assay and indication—not a TPS threshold.
Kantesti's educational explanation should preserve all 3 scoring labels rather than flatten them into positive or negative. When using AI report explanations safely, check that the original score, assay, and specimen remain visible; an AI-generated conversion without the underlying tissue counts is not clinically dependable.
Rincian laporan patologi apa sing penting saliyane skor?
A usable PD-L1 report should identify the specimen, assay, scoring method, numerical result, and adequacy assessment. Several commonly used protocols require at least 100 viable tumor cells, but minimum counts and acceptable specimen types depend on the particular test and cancer indication.
Antibody identifiers such as 22C3, 28-8, SP263, and SP142 describe different testing assays or antibody clones, not different PD-L1 proteins. Some assays show substantial agreement in selected settings, but laboratories should not assume universal equivalence across tumor types, scoring methods, immune-cell assessments, and treatment requirements.
The specimen date and site can change the interpretation of 1 reported number. A small primary-site sample taken before treatment may not represent a later metastatic deposit; ask whether the report describes the current treatment-setting specimen or archived tissue that the oncology team considers suitable.
Insufficient tissue is not PD-L1 negative. A sample with too few viable tumor cells, failed controls, extensive tissue change, or unsuitable processing may be unreportable; the practical next step is laboratory clarification, additional sections, or another suitable specimen—not assigning TPS 0% or CPS 0.
Comparisons between 2 reports need more than matching dates. Our test timing and comparability guide explains the general problem of comparing unlike measurements; for PD-L1, the extra checks are anatomical site, prior treatment, fixation, tissue adequacy, assay, and scoring system.
Kepiye jinis kanker ngowahi teges positif?
PD-L1 positivity is indication-specific, not a universal diagnosis. TPS thresholds such as 1% or 50% are familiar in non-small-cell lung cancer, while CPS thresholds such as 1, 5, or 10 appear in selected other cancer settings; the drug, stage, and regimen must accompany the cutoff.
For recurrent or metastatic head-and-neck squamous-cell carcinoma, KEYNOTE-048 evaluated CPS-defined populations. Pembrolizumab alone improved median overall survival in the CPS ≥20 group to 14.9 months versus 10.7 months with the comparator regimen, showing why a CPS threshold cannot be borrowed from a lung-cancer TPS report (Burtness et al., 2019).
Selected established pembrolizumab pathways use CPS ≥10 for unresectable locally advanced or metastatic triple-negative breast cancer with chemotherapy, and CPS ≥1 for certain persistent, recurrent, or metastatic cervical-cancer regimens. Those examples do not establish eligibility for every earlier-stage setting, drug combination, country, or funding pathway.
Gastric and gastroesophageal-junction cancers require particular care because treatment selection may also involve HER2 lan MSI/MMR, with PD-L1 requirements differing across regimens and jurisdictions. A serum marker described in our CA 72-4 interpretation guide cannot replace the tissue biomarker panel or define CPS.
Cancer diagnosis and treatment selection are 2 separate steps. Our persistent cough assessment guide addresses when lung symptoms need investigation; once cancer is confirmed, ask the oncology team to match the PD-L1 result to the current local product information and clinical pathway.
Apa sebabe regimen perawatan padha pentinge karo ambang skor
Immunotherapy alone and immunotherapy combinations can have different PD-L1 requirements. A TPS below 1% may rule out one PD-L1-selected monotherapy pathway without ruling out an appropriate chemotherapy–immunotherapy combination; these are different clinical decisions, not contradictory interpretations of the same result.
KEYNOTE-024 enrolled previously untreated advanced non-small-cell lung cancer with TPS ≥50% and no sensitizing EGFR mutation or ALK rearrangement. Median progression-free survival was 10.3 months with pembrolizumab versus 6.0 months with chemotherapy, supporting that specific high-TPS monotherapy setting—not every cancer with a score above 50 (Reck et al., 2016).
Ing KEYNOTE-189, pembrolizumab plus pemetrexed and platinum chemotherapy improved outcomes in previously untreated metastatic nonsquamous non-small-cell lung cancer without EGFR or ALK alterations. Twelve-month overall survival was 69.2% versus 49.4%, and benefit was observed across PD-L1 categories, including TPS <1% (Gandhi et al., 2018).
Combination treatment may address rapid disease progression differently from a single agent, but adding drugs also adds toxicity and monitoring needs. If a proposed regimen includes fluorouracil or capecitabine, tes DPYD sadurunge kemoterapi concerns treatment safety; it does not measure the PD-L1 pathway or predict the same benefit.
Kantesti iku sawijining platform interpretasi hasil tes getih AI that helps explain supporting laboratory measurements; it does not select between 1-drug and multidrug cancer regimens. Similarly, UGT1A1 and irinotecan safety address metabolism-related toxicity, illustrating why each biomarker should be matched to the specific medicine under discussion.
Apa asil PD-L1 positif njamin manfaat imunoterapi?
A positive PD-L1 result does not guarantee a response. In KEYNOTE-024's selected high-expression lung-cancer population, the objective response rate with pembrolizumab was 44.8%—substantial benefit for many participants, but clearly not a response in every person with TPS ≥50%.
The 44.8% response rate in KEYNOTE-024 describes a trial population under defined conditions, not an individual's calculated chance of success (Reck et al., 2016). Objective response also means measurable tumor shrinkage by trial criteria; stable disease and survival benefit are different outcomes that should not be collapsed into that single percentage.
PD-L1 is only 1 part of a broader immune environment. A cancer can show substantial staining while lacking effective immune-cell access, recognizable targets, or intact antigen presentation; these mechanisms help explain why expression enriches for benefit in some settings without functioning as a deterministic on–off switch.
Higher does not always mean better across different cancers and combinations. A CPS 30 in one disease cannot be ranked against TPS 60% in another, and the same CPS threshold may have different predictive value when used for monotherapy versus a combination that already provides benefit through other mechanisms.
Some melanoma immunotherapy regimens do not require a positive PD-L1 test, so a low score should not be interpreted using lung-cancer monotherapy rules. Our melanoma warning-sign guide addresses recognition and assessment, while treatment benefit must be discussed using disease-specific trial evidence and the person's overall condition.
Apa imunoterapi isih bisa ditawakake yen PD-L1 negatif?
PD-L1-negative cancers can still have appropriate immunotherapy options. TPS <1% or CPS <1 may exclude a particular PD-L1-selected regimen, but some combinations, earlier-stage pathways, and treatments selected by other biomarkers do not require PD-L1 positivity.
PD-L1-negative should first be translated into the laboratory's actual definition. TPS <1%, CPS <1, and an assay-specific IC-negative category are not identical measurements; an unreportable or inadequate sample is a fourth situation and should not be grouped with a technically valid negative result.
An MSI-high or mismatch-repair-deficient cancer may support particular immunotherapy pathways without PD-L1 selection, depending on the disease, stage, prior treatment, and local authorization. Tumor MMR testing and Tes genetik sindrom Lynch answer related but different questions: an abnormal tumor result does not automatically prove an inherited syndrome.
Other genetic findings may point toward targeted treatment or different planning rather than immunotherapy. A result discussed in our BRCA variant interpretation guide does not turn CPS 0 into CPS 10; clinicians combine distinct biomarkers without pretending they measure the same biological feature.
No PD-L1 requirement is not the same as no selection criteria. A regimen can still require a particular histology, stage, treatment history, organ function, or absence of an actionable driver alteration; ask whether 1 negative score changes only the proposed option or the broader treatment plan.
Kapan pangambilan sampel utawa skor sing cedhak ambang bisa dadi alasan kanggo ditinjau?
Sampling variation can change PD-L1 classification, especially near a treatment threshold. A CPS of 9 versus 10, or TPS 0.8% versus 1%, may prompt pathology review when the distinction would change an otherwise suitable treatment—but repeating every result is not automatically useful.
PD-L1 staining can be heterogeneous within 1 tissue block and between primary and metastatic sites. A small tissue examination may miss a highly expressing area or overrepresent it; the pathologist assesses the available viable tissue rather than assuming a single selected field describes the whole cancer.
Pretreatment and post-treatment specimens are not always equivalent. Chemotherapy, radiotherapy, and changes in the immune environment can alter expression, while decalcification of some bone specimens can impair antigen detection; ask whether a lower result reflects biology, processing limitations, or simply a different sampled site.
Borderline results require the actual assay rules, not homemade averaging. If 2 reports show CPS 8 and CPS 12, calculating CPS 10 does not create a newly validated result; the laboratory and oncology team should decide which specimen and assessment are appropriate for the treatment indication.
Kantesti cannot verify viable-cell counts, staining controls, or tissue suitability from a score alone. Our validasi klinis lan pengawasan should be read in that limited context; when another tissue procedure is considered, its risks and likely impact on treatment need to be weighed against the uncertainty in the existing result.
Biomarker liyane apa sing perlu ditliti bebarengan karo PD-L1?
Other biomarkers can take priority over PD-L1, depending on the cancer. In advanced non-small-cell lung cancer, molecular alterations such as EGFR mutations and ALK rearrangements affect treatment planning; in selected other cancers, HER2, MSI/MMR, or additional molecular findings may change the preferred pathway.
A high TPS does not cancel an actionable molecular finding. The pivotal KEYNOTE-024 lan KEYNOTE-189 populations excluded relevant EGFR or ALK alterations, so their results should not be applied unchanged to those groups; treatment sequence also matters because some targeted therapies and checkpoint inhibitors can interact through toxicity.
Tumor mutational burden, often measured in mutations per megabase, is a different biomarker from PD-L1. A threshold such as 10 mutations/Mb has been used in a specific tissue-agnostic treatment context, but assay differences, cancer type, authorization, and clinical setting prevent it from becoming a universal immunotherapy rule.
A liquid molecular test may find circulating tumor DNA, but it does not automatically replace tissue PD-L1 immunohistochemistry. The 2 tests measure different things—genetic material versus protein location within cells—and a negative liquid result may also reflect limited DNA shedding rather than absence of a tumor alteration.
Kantesti AI distinguishes the role of supporting laboratory markers from tissue-based treatment biomarkers in our nuduhake sawetara tandha sing relevan kanggo kinerja ora tau dijaluk.. A blood-cell ratio, LDH level, or serum tumor-marker concentration should not be used to manufacture TPS 50%, estimate CPS 10, or bypass an indicated molecular workup.
Pemeriksaan keamanan apa sing penting yen imunoterapi dianggep minangka pilihan?
PD-L1 scores predict neither treatment safety nor immune-related toxicity. A TPS of 90% does not make checkpoint treatment safer than TPS 1%; the team assesses medical history, organ function, medications, and the particular regimen separately from the tissue biomarker.
Checkpoint inhibitors can cause immune-related effects involving the thyroid, liver, lungs, bowel, kidneys, heart, and other organs. Baseline testing commonly includes liver chemistry, creatinine, thyroid measurements, and a complete blood count, with monitoring schedules varying by regimen; 1 normal baseline panel does not prevent later toxicity.
New chest pain, palpitations, fainting, or breathlessness during treatment requires prompt assessment because myocarditis, although uncommon, can be serious. Our myocarditis test interpretation guide explains why troponin supports evaluation but cannot determine the cause by itself; severe symptoms warrant emergency care rather than waiting for the next scheduled panel.
Kidney changes need interpretation against the person's own baseline and treatment exposures. A hypothetical creatinine rise from 0.8 to 1.6 mg/dL is a doubling even if the absolute value looks only modestly elevated; our kidney function testing guide explains supporting measurements, not an immunotherapy-specific treatment decision.
Pre-existing autoimmune disease, organ transplantation, ongoing immunosuppression, or previous severe immune-related toxicity can complicate treatment planning even when CPS is 100. Report new persistent diarrhea, worsening cough, jaundice, unusual weakness, or marked thirst promptly; neither a high PD-L1 score nor previously reassuring blood results justify delaying symptom assessment.
Apa sing kudu ditakokake nalika janjian karo onkolog?
Nggawa complete PD-L1 pathology report and ask which exact treatment decision it informs. Four useful starting questions are: Which score was used? Which cutoff applies? Is the specimen adequate? What options remain if the result is below the cutoff?
A hypothetical report reading 22C3, CPS 12, adequate tissue is still incomplete as a treatment answer until the cancer, stage, and regimen are specified. Ask whether CPS ≥10 is relevant to the proposed option, whether other biomarkers are pending, and whether a combination would be considered under different selection rules.
Request explanations of 3 outcomes separately: tumor shrinkage, duration of disease control, and survival. A trial's response rate is not the same as its survival benefit, while median survival is a group midpoint—not an individual deadline—and the balance between rapid control and treatment toxicity may change the preferred regimen.
Kantesti iku sawijining layanan interpretasi tes lab AI for supporting laboratory understanding, not independent immunotherapy eligibility assessment. If blood monitoring is planned, our dhasar kita can help organize previous values, units, medication lists, and collection dates so that the oncology team can compare results meaningfully.
Keep tissue scores separate from serial blood monitoring in 2 clearly labeled records. Our panduan tren keamanan obat explains why changes over time need context; our AI sing tanggung jawab also make clear that automated explanations should not trigger treatment changes without clinical review.
Publikasi panaliten lan watesan bukti PD-L1
PD-L1 interpretation should be grounded in cancer-specific trials and validated pathology methods. The 3 clinical references below address high-TPS lung-cancer monotherapy, lung-cancer combination treatment, and CPS-selected head-and-neck treatment; the 2 separate Zenodo publications concern other laboratory topics and do not establish PD-L1 thresholds.
KEYNOTE-024 supports a defined TPS ≥50% advanced lung-cancer population, whereas KEYNOTE-189 supports a particular combination across PD-L1 categories (Reck et al., 2016; Gandhi et al., 2018). Those different study designs explain why evidence for one regimen cannot be substituted for evidence supporting another simply because both drugs affect the same immune pathway.
KEYNOTE-048 assessed CPS-defined recurrent or metastatic head-and-neck cancer populations, including CPS ≥1 and CPS ≥20 groups (Burtness et al., 2019). When reading a trial, check the histology, stage, previous treatment, comparator, and endpoint; a subgroup survival finding does not automatically quantify an individual's chance of measurable shrinkage.
Kantesti's 2 Zenodo publications listed below are educational resources on complement/ANA testing and Nipah-virus diagnostics, not PD-L1 clinical trials or assay-validation studies. The pandhuan komplemen lan ANA concerns different laboratory questions, and a DOI identifies a deposited publication without independently establishing clinical validity.
Use the original pathology result and current local treatment information to resolve eligibility—not a generalized positive/negative table or an AI-generated score conversion. Our standar konten medis emphasize source relevance and uncertainty; ask your oncology team to document the 1 specific regimen, applicable threshold, and remaining alternatives.
Pitakon sing kerep ditakoni
Apa tegesé PD-L1 positif?
PD-L1 positif tegese asil jaringan wis nyukupi ambang tes lan skor tartamtu, kayata TPS ≥1% utawa CPS ≥1 ing kahanan sing cocog. Ambang kasebut gumantung marang jinis kanker, regimen perawatan, lan syarat perawatan lokal. Asil positif ora mbuktekake manawa imunoterapi bakal bisa, lan laporan kasebut kudune nyebutake skor numerik, ora mung tandha positif.
Apa bedane CPS lan TPS?
TPS ngukur persentase sel tumor sing isih urip kanthi pewarnaan membran PD-L1 sing memenuhi syarat, dene CPS nyakup sel tumor positif, limfosit, lan makrofag sing memenuhi syarat, dibagi karo sel tumor sing isih urip banjur dikalikan 100. TPS dilaporake saka 0% nganti 100%, lan CPS sing dilaporake diwatesi maksimal 100. Skor kasebut ora bisa dikonversi amarga CPS gumantung marang pewarnaan sel imun sing ora dietung dening TPS.
Apa CPS 10 tegese 10% kemungkinan imunoterapi bisa mujarab?
CPS 10 ora ateges kemungkinan 10% kanggo nanggapi imunoterapi. CPS minangka petungan pewarnaan jaringan sing nggunakake sel tumor sing isih urip minangka panyebut, dudu probabilitas tanggepan perawatan kanggo saben individu. CPS ≥10 ndhukung pilihan regimen tartamtu sing khusus kanggo kanker, nanging kanggo ngira-ngira manfaat sing mungkin uga dibutuhake diagnosis kanker, stadium, biomarker liyane, lan bukti kanggo perawatan sing diajokake.
Apa aku bisa nampa imunoterapi yen PD-L1 negatif?
Asil PD-L1 negatif ora ateges kabeh pilihan imunoterapi ora bisa digunakake. Sawetara kombinasi kemoterapi–imunoterapi lan jalur liya sing dipilih adhedhasar biomarker ora mbutuhake asil PD-L1 positif, sanajan TPS kurang saka 1%. Kelayakan isih gumantung marang jinis kanker, stadium, temuan molekuler, riwayat perawatan, kecocokan medis, lan persetujuan lokal; sampel jaringan sing ora nyukupi ora kena dianggep minangka asil negatif sing sah.
Apa TPS 50% dianggep PD-L1 dhuwur?
TPS ≥50% ing kahanan kanker paru-paru non-sel cilik tartamtu umumé diarani ekspresi PD-L1 sing dhuwur. Ambang iki digunakaké ing KEYNOTE-024, sing nyinaoni populasi tartamtu kanthi kanker paru-paru tingkat lanjut tanpa mutasi EGFR sing nyensitisasi utawa rearrangement ALK. TPS 50% ora padha karo CPS 50 lan dudu ambang universal kanggo saben kanker, stadium, utawa regimen imunoterapi.
Apa PD-L1 iku tes getih, lan apa perlu diulang?
Skoring klinis PD-L1 kanggo CPS lan TPS biasane nggunakake jaringan kanker sing diawetake lan dipriksa nganggo imunohistokimia, dudu sampel getih rutin. Evaluasi ulang bisa migunani yen jaringan ora nyukupi, asilé cedhak karo ambang sing bisa ngganti keputusan kayata CPS 10, utawa spesimen liya luwih cocog. Tim onkologi lan patologi kudu mutusake apa tinjauan ulang, irisan tambahan, utawa spesimen liya bisa uga cukup ngowahi perawatan nganti layak nglakoni upaya lan nampa risiko prosedur sing gegandhengan.
Entuk penjelasan babagan asil tes getih sampeyan
Unggah laporan laboratorium sampeyan lan AI Kantesti bakal nerangake saben biomarker nganggo basa sing prasaja sajrone sawetara detik. Digunakake luwih saka 2 yuta wong ing saindenging donya.
Referensi
- Klein, T., Mitchell, S., & Weber, H. (2026). Pandhuan Tes Getih C3 C4 Komplemen & Titer ANA. Riset Medis AI Kantesti. DOI
- Klein, T., Mitchell, S., & Weber, H. (2026). Virus Nipah: Pandhuan Tes Getih kanggo Deteksi Awal & Diagnosis 2026. Riset Medis AI Kantesti. DOI
- Reck M et al. (2016). Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. DOI
- Gandhi L et al. (2018). Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine. DOI
- Burtness B et al. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet. DOI
- 2M+Tes sing dianalisis
- 127+negara-negara
- 100+Basa
Babagan tim medis
Sinyal Kepercayaan E-E-A-T
Pengalaman
Tinjauan klinis sing dipimpin dokter babagan alur kerja interpretasi lab.
Keahlian
Fokus kedokteran laboratorium babagan carane biomarker tumindak ing konteks klinis.
Kewibawaan
Ditinjau sacara medis dening Dr. Thomas Klein, kanthi kontribusi saka Dr. Sarah Mitchell lan Prof. Dr. Hans Weber.
Kapercayan
Interpretasi adhedhasar bukti kanthi tindak lanjut sing cetha kanggo nyuda rasa kaget.
Sanggahan medis
Artikel iki mung kanggo tujuan edukasi lan ora dadi saran medis. Tansah konsultasi karo panyedhiya layanan kesehatan sing mumpuni kanggo keputusan diagnosis lan perawatan.
Diterbitake · Hubungi tim editorial
Diterbitake dening Kantesti Ltd, kadhaptar ing Inggris & Wales, nomer perusahaan. 17090423, London, Britania Raya.
